Tuesday, November 3, 2009

Salix Pharmaceuticals Secures Additional Intellecutual Property Relating to Rifaximin

Nov 3, 2009 - Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,612,199 (the ˜199 patent) entitled “Polymorphic Forms Alpha, Beta, and Gamma of Rifaximin”. The patent issued November 3, 2009 and provides protection until June 2024.

The details can be read here.

No comments: